Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Cardano Price Nears Support as Bearish Flag Targets Breakdown to $0.192
16+ hour, 10+ min ago (663+ words) Cardano price traded near $0.208 on Sept. 13 after failing to extend its latest recovery. ADA remained close to the $0.205 support area, where a bearish flag pattern has kept downside risk in focus. The token has fallen from above $0.22 over the past…...
Moonwalk reloads with $70M and new RNAi prospects for obesity
6+ day, 3+ hour ago (331+ words) The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027. When Moonwalk Biosciences launched in 2024, it set ambitious plans to mine the epigenome for…...
Boycott launched against American Diabetes Association includes journal
2+ day, 20+ hour ago (743+ words) By Chelsea Cirruzzo, Helen Branswell, and Elizabeth Cooney Good morning. Chelsea Cirruzzo here. Today we remember 25 years since the 9/11 terrorist attacks. While I was too young to have many recollections of the attack, I did grow up in New York…...
VIRAL GELATIN TRICK FOR WEIGHT LOSS: Does It Actually Deliver Results?
3+ day, 10+ hour ago (21+ words) Cal Poly Pomona Javascript is required to view this panorama....
GPCR: Oral GLP-1 and amylin programs advance with strong data, robust funding, and strategic focus
3+ day, 10+ hour ago (76+ words) TradingView Multiple phase III and II studies are underway for oral GLP-1 and amylin programs, with strong efficacy, safety, and innovative trial designs highlighted. The company is well-funded, maintains a robust IP portfolio, and is pursuing strategic partnerships to maximize…...
GPCR: Advancing oral GLP-1 and amylin programs with strong data, robust funding, and strategic focus
3+ day, 11+ hour ago (78+ words) TradingView Multiple late-stage clinical programs are advancing, with strong efficacy and safety signals for both oral GLP-1 and amylin candidates. The company is well-funded, has a robust IP portfolio, and is pursuing strategic partnerships to maximize value as the oral…...
Oral GLP-1 Therapeutics Market to Soar to USD 137.36 Billion by 2035, Growing at 35% CAGR – SNS Insider · Business Upturn
3+ day, 12+ hour ago (453+ words) U.S. Oral GLP-1 Therapeutics Market to Reach USD 70.50 Billion and Europe USD 19.72 Billion by 2035 as Oral Wegovy Approval, Non-Peptide Candidates, and Telehealth Access Drive Growth. Oral GLP-1 Therapeutics Market Key Highlights Oral GLP-1 Therapeutics Market Overview Higher costs of treatments and…...
Fifth Avenue, Roosevelt Park in Arnold could get curb ramps by spring 2028
3+ day, 21+ hour ago (291+ words) Fifth Avenue and Roosevelt Park in Arnold could get curb ramps compliant with the Americans with Disabilities Act if awarded federal funding for the project. About 26 curb ramps could be added along Fifth Avenue, with four being at Roosevelt Park,…...
Once-weekly oral GLP-1 tablet reaches its first human trial
4+ day, 1+ hour ago (258+ words) Gan&Lee dosed the first of 112 participants; WHO projects US$3 trillion in annual obesity costs by 2030 Gan&Lee says it developed GZC8072 independently, basing the candidate on native GLP-1 and targeting type 2 diabetes mellitus (T2DM) alongside weight management in people with obesity…...
iCare IC1000™: Precision Made Effortless
4+ day, 1+ hour ago (387+ words) Revenio Group Corporation | Press Release | September 10, 2026 at 09:00:00 EEST iCare, a subsidiary of Revenio Group, announced today the launch of iCare IC1000™, the next-generation handheld tonometer built on the proven iCare rebound tonometry platform and designed to bring guided operation to handheld…...